responsible business supplement progress commitments gsk responsible business supplement approach health behaviour people planet data summary supplement commercially successful contents operating responsibly improve statements lynn elsenhans cover image peoples health benefit society chair corporate responsibility committee sir andrew witty ceo well create value shareholders independent commentary aron cramer report provides performance president ceo bsr update responsible business commitments across four key focus corporate responsibility priorities areas health behaviour approach responsible business gsk people planet overview supplemental information highlights emerging issues gsks annual report approach responsible business health arthur biologist working cancer cell biology new smart lab pennsylvania usa developing innovative products improving access healthcare patients consumers around world gsk outlined intent commit future portfolio indicate progress commitments using cancer treatments patent pooling explore following key behaviour concept medicines patent pool mpp help work needed embedding values throughout business including address increasing burden cancer developing ways research develop sell market products countries would first company take step work needed get commitment schedule since established mpp track people successful accelerating access hiv tb hepatitis c work ongoing creating inspiring supportive work environment medicines lowincome middleincome countries encourages employees develop capabilities voluntary licensing arrangements expanding progressing well achieve best approach oncology would enable generic versions next generation immunooncology epigenetic therapies able demonstrate clear deliverables good progress planet currently clinical development made available towards completing commitment managing environmental impacts operations least developed countries lowerincome countries products across life cycle reduce carbon emissions certain middleincome countries receive completed water use waste regulatory approval commitment completed data summary key data gsk responsible business supplement approach health behaviour people planet data summary cr committee chairmans statement ceos statement chair gsks corporate responsibility committee role gsk strong commitment operating responsibly playing help gsk identify works meet needs shareholders part meeting societys biggest healthcare challenges wider society past decade seen commitment place committee reviewed performance companys access medicines centre business approach responsible business commitments evolving challenges innovation focused diseases impact poorest countries opportunities across four focus areas covered report malaria changes made commercial model key topic continued balance need return sales marketing practices investment innovation need price products affordably addressing global health challenges corporate support access patients responding took steps address serious responsibility providing clear update commitments humanitarian crisis global health challenges responding humanitarian crisis report designed supplement information responsible areas syria southern sudan pledged offer essential committee reviewed areas syria business annual report focused tightly performance vaccines lowest price organisations supporting refugees performance gsks responsible business commitments southern sudan wake recent global health threats ebola zika companys pledged offer important company remains open objective feedback announced proposals biopreparedness organisation dedicated responsible business related responsible business reporting year welcome essential vaccines developing new vaccines prevent future outbreaks early commitments valuable insight provided aron cramer president ceo bsr lowest price also pledged support coalition epidemic preparedness complete letter see innovation cepi global collaboration research develop new evolving challenges organisations vaccines future epidemics looking future opportunities supporting refugees past decade company made great progress also understand patient concerns pricing medicines across four responsible business priorities would like take opportunity developed countries take thoughtful responsible approach focus areas covered thank andrew witty outstanding personal leadership area example us six latest new medicines launched similar prices medicines aim supersede report looking forward committee work new ceo developing countries introduced new approach filing emma walmsley business continue embed enforcing patents ip based countrys economic maturity responsible business priorities necessary seek evolve responsible business commitments ensure continued play important role fight antimicrobial support companys future strategy meet changing resistance advanced new antibiotic pipeline expectations society moved towards phase iii trials positive phase ii results building achievements im pleased actions recognised gsk topping fortunes change world list access medicine index latter fifth consecutive time lynn elsenhans last report retire nearly years ceo chair gsks corporate responsibility committee years employee leave gsk confident company wellpositioned build progress made sir andrew witty chief executive officer gsk responsible business supplement approach health behaviour people planet data summary benchmarks external perspective reporting commentary aron cramer president ceo bsr external benchmarking gsks responsible business supplement strong statement also areas gsk could stretch efforts intentions actions achievements gsk topped access medicine transparency gsks approach tax welcome given index fifth consecutive one signal accomplishments clear link gsks complexity issue however additional detail would help time since biennial assessment began business strategy central public health issues strategy readers understand better gsks approach beginning also designed address gsk distinguished past important issue overall performed well first ever access several years staying resolutely focused important past year saw numerous political developments great vaccines index leading three issues faces global healthcare company approach significance gsk public health position global categories consideration well represented document companies generally would good hear gsks vision gsks approach captures important ways public health reference developments contribute thriving global population health challenges scored within top sector company notes progress carbon emissions mature economies also questions public likely dow jones sustainability index needed meet targets clarity plan get company gsks profile purpose regard assesses companies economic would welcome approach passes first important test companys environmental social performance efforts responsible business w ith respect gsks people would valuable include included world europe assessment employee base along lines engagement indexes several elements covered supplement particularly survey results comparable measure understand laudable including workforce views situations member g sks performance access medicines recognised closing also worth noting importance leadership ftsegood index since index access medicines index important strong point access andrew witty demonstrated vision ceo designed measure performance pricing perhaps important questions sector coupled follow across organisation makes real companies demonstrating strong faces gsks continued leadership commended difference emma walmsley takes ceo post clear environmental social governance g sk focusing wide array crucial public health wellpositioned maintain extend gsks leadership esg practices challenges including pandemics noncommunicable diseases problems associated changing demographics eg alzheimers clear storyline gsks leading approaches awarded agrade transparency several domains including payments health cdps climate change programme one professionals tax clinical trials gsk long leader aron cramer global companies recognised area excellent see ongoing commitment president ceo bsr companies responding survey g sk distinguishes focusing attention overall healthcare system increasingly important business dedicate strengthening infrastructure enable systemic improvements achieved score cdps water detail provided compliance business principles programme first time one ethical behaviour welcome global companies gsk responsible business supplement approach corporate responsibility priorities responsible business priorities aligned business strategy informed stakeholder insights key health behaviour people planet mission help people feel better live longer high researching developing medicines vaccines consumer healthcare products improve peoples lives pricing antibribery corruption growing business extending access medicines ensuring longterm commercial success well improving access healthcare peoples health creating value shareholders delivering sales marketing practices economic benefits society transparent reporting product innovation communications operating responsibly also supports ability attract retain talent build trust patients consumers customers clinical trial conduct payers stakeholders influence licence operate product safety quality supply gsk contributes directly indirectly economic growth countries tax charitable support employing human rights labour intellectual property people counterfeiting inclusion diversity wellestablished longterm responsible commitments energy use sit across four areas health behaviour people climate change tax economic contribution planet established priorities areas comprehensive materiality assessment identify issues charitable donations important stakeholders impact high business success reviewed validated analysis using range privacy data security sources including employee feedback investor insights uns animal research sustainable development goals global reputation research ethical supplier standards also conducted indepth interviews representatives water use employee safety key stakeholder groups including patient advocacy groups ngos waste recycling wellbeing peer groups investors think tanks academia material talent attraction issues considered relation commercial strategy retention impact business biodiversity medium r ead impact business success materiality process public policy sdgs sredlohekats ot ecnatropmi health behaviour people planet data summary prioritising material issues gsk responsible business supplement approach health behaviour people planet data summary overview health read emerging issues expanding reducing responding fighting malaria tackling antimicrobial neglected tropical graduated approach child mortality new diseases resistance diseases companies like continued face range ip challenges including bn stakeholder concerns pricing value medicines pressure public debate pharmaceutical expanded european proposing world health opened institute industrys approach pricing continued across graduated approach medicines agency create organization confirmed infectious diseases donated one key markets particularly case us filing enforcing endorsed chlorhexidine biopreparedness funding public health billion albendazole uncertainty new administration shape patents ip widen antiseptic gel organisation develop committed enable china address local tablets prevent healthcare understand payer patient concerns access medicines newborn umbilical vaccines major pilot implementation health threats posed lymphatic filariasis affordability healthcare leading efforts develop poorest countries cord infections global health threats rtss malaria antibiotic resistance intestinal worms sustainable solutions see detail developing countries future vaccine three settings infectious diseases subsaharan africa humanitarian crisis humanitarian crisis affecting areas syria south sudan continued potentially leaving displaced people unable access healthcare vulnerable vaccinepreventable disease response pledged offer essential vaccines lowest price organisations behaviour read people read planet read supporting refugees governments unable assist see detail code conduct working graduate employees partnership carbon emissions water use hcps prevention global pandemics world health organization declared zika virus international public health emergency becoming increasingly important improve preparedness global health systems continue see rise public health outbreaks seeking work governments mandatory annual longer pay gsk topped partnership cut used multinational organisations ngos enhance training code prescribing healthcare times top prevention operational carbon less water conduct professionals graduate employers programme offering emissions scope operations preparedness potential future outbreaks diseases completed speak list rd unprecedented see detail employees prescribers ranked th overall access preventive since total less complementary workers medicines healthcare almost value chain emissions tax vaccines employees risen continues scrutiny key stakeholders family members extend access countries medicines approach tax taken multinational companies working understand responsibility pay appropriate amount address tax transparent manage tax affairs see approach remaining represents employees complete training required timeframe subject disciplinary action see employees still within completion timeframe eg new starters gsk responsible business supplement approach health behaviour people planet data summary health tackling biggest global health challenges promoting open innovation meet unmet medical needs making medicines vaccines accessible strengthening healthcare systems section innovation unmet medical needs completed better access medicines progressing well vaccines building products better meet needs progressing well strengthening healthcare infrastructure progressing well fighting malaria progressing well eliminating controlling neglected progressing well tropical diseases eradicating polio progressing well access antiretroviral treatment hiv progressing well reducing child mortality progressing well improving offer lowest vaccine prices organisations gavi affordability vaccine alliance supports countries low gross national developing income since countries pledged deliver million doses pneumococcal vaccine deeply discounted price gsk responsible business supplement approach health behaviour people planet data summary commitment performance update innovation unmet medical needs combatting antibiotic resistance using years experience antibiotics examples projects include completing latter stages commitment adapt open innovation rd preclinical development new tuberculosis tb candidate tackle resistance model currently used diseases developing drug begin phase clinical trials antitb world ddw apply areas great unmet molecule progressed towards preclinical candidate selection medical need scientific challenge including infectious disease alzheimers disease tb development tools discovered predicttb crossindustry collaboration partners coled gsk transferred gsk research completion completed ongoing project noncommunicable diseases ncds outlined intent commit future portfolio cancer progress treatments patent pooling help address increasing burden cancer developing countries see addition early committed working governments multinational one pharmaceutical companies sign organisations ngos enhance preparedness potential access accelerated initiative commitment jointly invest future outbreaks disease wake recent global health million three years fight cancer ncds threats ebola zika growing consensus low lower middle income countries resistance antibiotics major public health crisis world needs better prepared global health threats people dying every year drug resistant infections africa ncd open lab following review process years expertise antibiotics committed continuing proposing create permanent biopreparedness involving external experts five projects covering cardiovascular research area organisation bpo rockville maryland vaccines global disease oncology chronic respiratory disease chronic kidney rd centre develop vaccines major global health threats advanced antibiotic pipeline gepotidacin moving disease diabetes recommended funding far final phase clinical testing granted qualified future bpo would operate noprofit noloss basis first projects looking severe asthma across east infectious disease product status food drug administration funding governments nongovernmental organisations africa led makerere university uganda began april fda would expedite review future us filing novel drug also pledged support coalition epidemic november launched call proposals developed collaboration us governments biomedical preparedness innovation cepi global partnership million available provide seed funding ten early career advanced research development authority governments industry funders research develop african scientists vaccines also make key contribution area preventing new vaccines future epidemics bacterial viral infections averting need antibiotics pharmacog innovative medicines initiatives sixyear addition potential new vaccines pipeline including response outbreak zika working paneuropean partnership dementia developing new targeting diseases like b streptococcus bacterium vaccines research center national institutes health methods track progression alzheimers disease identify us evaluate potential vaccine patients risk rapid onset identified criteria opened institute infectious diseases public health china address local health threats posed antibiotic resistance reduce cost drug development better identification open innovation symptoms gsk founding partner million dementia working companies government organisations open innovation lab tres cantos spain external scientists discovery fund continue work wellcome trusts set targets reduce antibacterial resistance building commitment access expertise resources develop new neuroimmunology consortium launched million davos declaration combating antimicrobial resistance innovative medicines diseases developing world project investigate whether mood disorders alzheimers members innovative medicines initiatives newdrugsbadbugs since tres cantos supported research projects treated targeting immune system programme work partnership industry academia biotech visiting scientists results lab organisations combat antibiotic resistance europe led papers scientific publications four patent applications included wipo research patent pool read online open innovation read online open innovation approach tb antibiotic resistance gsk responsible business supplement approach health behaviour people planet data summary better access medicines vaccines graduated approach intellectual property expanded approach filing enforcing fully implemented price viread china treatment commitment embed flexible pricing chb lower countries covered patents reflect country 's economic maturity strategy innovative business models countrys reimbursement policies commitment significantly prescription medicines vaccines increase expand access chb patients living china internationally recommended firstline treatment usage among less able access afford products supporting affordability developed countries understand payer patient concerns affordability healthcare leading efforts develop sustainable solutions progressing well us six latest new medicines launched similar prices medicines aim supersede also integrated three patient assistance programs paps one progress gsk patient assistance program gskforyoucom designed simplify improve programme experience eligible uninsured improving affordability developing middleincome countries patients patients medicare part prescription drug plan equitable pricing strategy medicines vaccines based paps provided gsk prescribed medicines vaccines country disease area product type patients ability pay valued cost goods sold million patients expanded existing approach filing enforcing least developed countries since capped prices also continued engage payers eu markets patents ensure balance need protect intellectual patented medicines vaccines eu balance affordability ensure access patients today property countrys economic maturity france germany italy spain uk long manufacturing work governments build health system sustainability longer file patents medicines leastdeveloped countries costs covered offer lowest vaccine prices organisations support ongoing innovation medicines achieved ldcs lowincome countries lower middle income countries gavi vaccine alliance supports countries reimbursement eu markets ellipta portfolio lmics apply patents believe appropriate gni per head less since pledged also offer licences allow supplies generic versions deliver million doses synflorix pneumococcal vaccine supporting refugees medicines countries g countries years deeply discounted price manufacturing scale response humanitarian crisis committed supply continue seek full patent protection highincome countries allowed us make incremental cost efficiencies enabled us essential vaccines lowest price internationally recognised uppermiddleincome countries g countries think offer additional price reduction delivered civil society organisations csos use acute humanitarian appropriate million doses synflorix vaccine million situations first vaccine covered commitment line approach viiv healthcare extended existing doses vaccine rotavirus gastroenteritis rotarix pneumococcal vaccine synflorix helps maintain stable licence agreement medicines patent pool mpp adult vaccination programmes times great humanitarian need formulation dolutegravir treatment hiv include vast middleincome countries patients benefit equitable governments unable assist majority lmics see pricing strategy prices established based upon socioeconomic factors within country example egypt investing communities also outlined intent commit patent pooling differentiated products within respiratory portfolio global community investment totalled million future portfolio cancer treatments exploring mpp concept could help address increasing burden cancer offered mirror income levels meet socioeconomic compared million donated medicines developing countries working towards making information segments within society approach enabled number worth million valued cost goods sold support current future patent portfolio freely available respiratory patients treated double last five years includes product donations support humanitarian aid distributed viiv healthcare global specialist hiv company majority owned gsk partners americares direct relief ima world health map year committed reduce price viread international project hope donated million firstline chronic hepatitis b chb treatment china cash communities worldwide figure includes response worldwide humanitarian relief example contributing cash zikaaffected countries latin america read online read online access healthcare gavi commitment work refugees ip access medicines developing countries gsk responsible business supplement approach health behaviour people planet data summary building products better meet needs strengthening healthcare infrastructure fighting malaria commitment continue build core range commitment continue work partners commitment build year commitment products formats better meet needs support strengthening healthcare contribute fight malaria people across globe including less infrastructure anticipate could improve continued rd investment partnerships able access afford products access healthcare million underserved ground people vs progressing well progressing well progressing well progress progress progress committee european medicines agency granted gsk reinvests profits pharmaceuticals rtss vaccine aims protect children p falciparum positive scientific opinion antiseptic gel help consumer healthcare products least developed countries common strain malaria responsible cases prevent umbilical cord infections newborns created gel ldc strengthen healthcare infrastructure globally phase iii trials rtss received positive opinion reformulating antiseptic ingredient chlorhexidine used strategic partnerships amref health africa care international european medicines agency shown corsodyl mouthwash working save children save children since invested million vaccine could considerable public health impact make sure gel reach vulnerable marginalised countries reached million people trained used combination malaria control measures children approved local regulatory applications frontline health workers continuing expand frontline world health organization confirmed funding make gel available notforprofit price share health workers programme beyond ldcs include countries committed enable pilot implementation rtss three manufacturing knowledge made others subsaharan africa nigeria south africa ghana settings subsaharan africa due begin early partnership bill melinda gates foundation zambia trained entrepreneurs sell also begun paediatric study assess safety developing thermostable vaccines prevent diseases products underserved communities live well social pharmacokinetics tafenoquine treatment p vivax strain endemic hot areas preliminary results show enterprise set barclays care international malaria found primarily asia latin america patients pneumococcal vaccine synflorix remain stable eight children mozambique registered mobile six months years old phase iii trial tafenoquine weeks c reminders vaccination visits recorded adults completed patient recruitment results also developing products help patients manage mvaccination pilot vodafone also presented research also resulted discovery cost treatment enabling buy little time supporting preventative measures cervical cancer preclinical antimalarial candidate evaluated singleunit inhaler products ventolin rotacaps work marie stopes international providing progression clinic year rotahaler registered three countries support vaccinations screenings treatment women completed work africa malaria partnership access critical medication bangladesh madagascar sierra leone pink reached million people increased knowledge ribbon red ribbon partnership malaria prevention control early treatment among collaborations african universities communities subsaharan africa work malaria expanded fiveyear million commitment comic including training scientists pan african relief partnership launched december chemistry network partnering establishment announced first grants organisations fighting malaria east african supply chain centre excellence rwanda improving health tanzania mozambique read online giving mothers babies healthier start read online read online protecting mothers newborn babies reinvesting healthcare corporate partnerships fighting malaria fronts gsk responsible business supplement approach health behaviour people planet data summary eliminating controlling neglected tropical diseases eradicating polio access medicines index harnessing partnerships expertise commitment help eliminate control ten commitment continue support global reach extend access healthcare neglected tropical diseases ntds affect objective eradicating polio providing billion people including elimination vaccines unicef achieved lymphatic filariasis lf continued investment rd ongoing product donations contribution london declaration ntds progressing well progressing well progress progress donated one billion tablets albendazole supplied million doses oral million lf million deworming bringing polio vaccine global eradication effort also supported topped access medicine index fifth consecutive time since began index independent total donated since seven billion researchers switch trivalent bivalent vaccine measure top pharmaceutical companies efforts improve estimate number people risk lf almost halved since undertaken globally aprilmay scientists access healthcare developing countries million fewer life years lost due illhealth disability world health organization recommended transition early death potential us billion savings longterm vaccine targeting types polio type described accessoriented company gsk recognised healthcare costs income loss result programme detected since reduces risk clear strategy increasing access medicines aligns corporate strategy leading peers three indexs kinetoplastid discovery performance unit dpu tres reemergence type vaccine seven categories research development pricing manufacturing cantos collaborating researchers university gsk maintains stockpile monovalent type vaccine mopv distribution product donations also made significant dundee scotland develop new treatments another ntd case unexpected outbreak may able strides capacity development visceral leishmaniasis two candidates currently preclinical respond rapidly whos request type index cites companywide ownership access key strength development step prior clinical trials outbreak nigeria getting mopv vaccines ready together commitment research development low part novartis transaction acquired rabipur rabies shipment three days middleincome countries highpriority medical needs vaccine main supplier unicef despite polio cases decreasing since final steps gsk ceo sir andrew witty commented fundamental prequalified rabies vaccines eradication polio extraordinarily challenging changes made business model enable us make products available affordable possible generating gsk vaccines institute global health continued make whos goal ending polio unlikely met returns need sustain business invest research progress additional grant monies received shigella gsk continue support eradication effort providing since previous assessment achievements include candidate vaccine advancing clinical trials significant additional volume oral polio vaccine doses progression malaria candidate vaccine creation reserve stock working partners find longerterm africa open lab noncommunicable diseases extension solutions bulk oral polio vaccine production equitable pricing strategies products delighted recognition achievements date know remain focused extending access healthcare programmes outlined report read online tackling ntds read online read online reaching unreached report london declaration unicef information polio gsk access medicine index gsk responsible business supplement approach health behaviour people planet data summary access antiretroviral treatment hiv reducing child mortality supporting children living hiv commitment viiv healthcare began new collaboration paediatric european commitment continue invest innovative continue research new treatments increase access network treatment aids foundation increase crosssector partnerships reduce child mortality medicines care people living hiv funding develop optimal treatment strategies achieve remission specifically children living hiv around world support unaids deliver progressing well ambition also work aids conference durban viiv healthcare received first ever public recognition award global communities combat stigma paediatric antiretroviral commitment action recognise discrimination associated hiv exceptional efforts expand access hivaids treatment progress children committed help save one million childrens lives progressing well working communities pioneering million partnership save developed ambition go beyond children reached additional million children pharmaceutical solutions supporting efforts improve care lifesaving interventions bringing total million control epidemic initiative mapping children since partnership began since progress hiv free future also continue support community one million children screened malnutrition viiv healthcare extended existing licence agreement based hiv education prevention programmes around world underfives immunised medicines patent pool cover lower middle income viiv healthcares positive action programmes children vaccinated measles polio countries adult formulation hiv drug dolutegravir advancing hiv treatment treated diarrhoea malaria pneumonia means adults living hiv developing world december viiv healthcare announced positive results together establishing models tackle child mortality covered licence agreements policy lower middle first phase iii studies twodrug hiv treatment regimen first democratic republic congo kenya replicated income countries enables adult formulation dolutegravir various phase iii studies evaluate innovative treatment elsewhere since trained community made available generic manufacturers royalty option also launched partnership national institute professional health workers equipped improved fees tiered depending national gdp following approval health first large phase iii trial study cabotegravir single upgraded health clinics continue improve healthcare relevant regulatory authorities agent prevention finally continued development mothers children working together us food drug administration fda investigative attachment inhibitor patients failed countries including humanitarian crisis disaster zones european medicines agency approved reduction weight treatment longer keep hiv control using received ethical corporation award best limit treatment hiv dolutegravir meaning current medicines private sector ngo partnership collaboration save children adolescents aged years old eligible children receive treatment viiv healthcare global specialist hiv company majority owned gsk burkina faso years campaigning save children people living hiv know hiv status diagnosed receive fda also approved first generic version dolutegravir support gsk culminated groundbreaking new sustained antiretroviral therapy receiving therapy undetectable manufactured aurobindo pharma made viral load legislation offer free healthcare children five available countries covered licence addition dolutegravir pregnant women made available first line hiv treatment part national addition work save children provided health programmes brazil botswana million reducedprice vaccines protect children diseases longrunning work gavi see read online adults living hiv viiv healthcare developing world covered read online positive action programmes licence agreement dolutegravir save children partnership gsk responsible business supplement approach health behaviour people planet data summary behaviour values underpin everything ensuring rigorous safety standards development manufacture new medicines interacting ethically healthcare professionals patient groups political stakeholders section ethical conduct progressing well promoting values sales progressing well marketing practices transparency clinical trial data completed rigorous patient consumer safety progressing well minimising animal testing track ensuring ethical interactions progressing well promoting human rights track working third parties track industry fundamentally changed commercial practices leading approach ensure sales marketing underpinned values working operate since january healthcare stopped paying healthcare professionals speak professionals prescribers medicines vaccines gsk responsible business supplement approach health behaviour people planet data summary commitment performance update ethical conduct approach tax substantial business employment presence reporting investigating concerns many countries around world pay significant amount commitment continue strengthen centrally track misconduct allegations concerns tax including corporation business taxes well valuesbased culture training people multiple speak channels offer people within outside gsk taxes associated employees understand standards expected encouraging reporting opportunity ask questions voice concerns anonymously responsibility pay appropriate amount tax fully support confidentially independent third party phone online concerns embedding values efforts ensure companies appropriately transparent continued raise awareness channels tax affairs managed provide detail way measure employee performance reporting concerns misconduct received approach tax tax policy annual report reports multiple speak channels progressing well reduction concerns raised reviewed part approach align investment strategies formal investigations initiated response countries already substantial economic frequent categories allegation employee performance activity government policies promote tax regimes relations product promotion attractive business investment transparent intent progress available relevant tax payers uk patent box disciplinary action expect employees live values patient focus take disciplinary action employees fail act line relationship tax authorities seek maintain integrity respect transparency policies employees disciplined policy open positive relationships governments tax authorities violations including employees disciplined worldwide welcome constructive debate taxation policy updated code conduct accompanying annual failing complete mandatory training code conduct international tax framework support oecd g training give people deeper understanding apply antibribery corruption within required timeframe principle tax paid throughout supply chain values everyday activities total disciplined employees received documented warning profit making activities take place training people received verbal warnings transfer pricing line oecd guidelines base employees complementary workers dismissed agreed leave company voluntarily transfer pricing policy armslength principle support completed mandatory training code conduct code attendance payroll remains biggest type violation transfer prices economic analysis reports conduct training helps employees understand manage range includes disciplinary actions related risks associated daily business activities including employee absence punctuality misstating hours worked tax havens engage artificial tax arrangements zero tolerance approach bribery corruption without business commercial substance people working high risk roles also completed additional indepth eemmpploloyyeeeess disicsicpilpinliende idn corporation tax group paid corporate income training antibribery corruption help understand bbrreeaakkddoowwnn tfy tpyepse osf opfo pliocyli cviyo vlaiotiolantion tax million million profits manage particular challenges may face daily work million million corresponding tax ethics compliance professionals across charge profits million million business enhanced skills knowledge ethics attendance payroll compliance academy bringing total number certified training completion ethics compliance professionals good manufacturing distribution practices conducted senior management assessments local work regulation violations evaluate well values embedded within specific marketing promotional activities business areas also continued independent values code conduct assurance programme provides assessment progress falsification documents embedding values throughout organisation travel expense environment health safety read online read online approach tax gsk policies codes standards annual report gsk responsible business supplement approach health behaviour people planet data summary promoting values sales marketing practices transparency clinical trial data publishing payments made hcps commitment continue drive valuesbased transparently report payments hcps activities commitment transparent possible approach sales marketing practices across advisory boards market research help us develop medicines clinical trial data including publishing world interests consumers vaccines meet patients needs disclosing clinical study reports without patientlevel data payments made hcps markets across europe including patients core outcome trials medicines conducted russia ukraine australia japan usa gsk within appropriate process making fulfilling requirements european federation progressing well available researchers access anonymised pharmaceutical industries associations disclosure code patient level data scientific enquiry disclosing payments named individuals disclosing aggregate basis payments relating research development achieved named disclosure completed ongoing progress significantly higher companies across industry fundamentally changed commercial practices also adopted consent contract policy europe ensure sales marketing underpinned values means work hcps withhold consent wherever operate continued make strong progress progress gsk publish transfers value received us area anticipate marking commitment reportable activities continue lead industry clinical study transparency complete report embedding valuesbased approach sales making information available trials whether positive engaging healthcare professionals negative gsk first company publish clinical sales teams worldwide incentivised based technical since january stopped paying prescribing healthcare study reports csrs form basis submissions knowledge support hcps improve patient care rather professionals hcps speak prescribers regulatory agencies individual sales targets valuesbased approach received medicines vaccines key milestone working positive feedback hcps survey us hcps reports summaries towards since announcing december industryleading gsk ranked first customer trust fourth year row trial results publicly available also began approach work hcps customer value third time providing plain language summaries clinical studies strengthened online resources supplement reaching resolution securities exchange present results way readily understandable information provided salesforce significantly commission sec general audience including study participants expanded global team inhouse medical experts provide reached resolution us sec regarding researchers submit proposals request access information medicines vaccines hcps ways investigation commercial practices countries outside anonymised patientlevel data behind results around convenient around medical experts us sec investigation conducted full cooperation clinical trials clinicalstudydatarequestcom dedicated engaging hcps also us accepted outcome resolution us website provides data industry sponsors engage hcps part roles department justice doj also concluded investigation including gsk also request combined data trials following medical product information sessions gsk experts matters taking action sec doj one industry sponsors independent panel countries hcps agreed investigations initiated part industrywide inquiry appointed wellcome trust reviews research proposals interaction helped make informed decision benefiting reaching resolution sec took account changes scientific merit end proposals patient care around rated experience superior made commercial practices last years approved research teams granted access similar interactions pharmaceutical companies anonymised patientlevel data investigations uk serious fraud office sfo regarding china business operations ongoing group responding sfos requests read online read online sales marketing practices clinical study register european federation pharmaceutical industries associations data transparency gsk responsible business supplement approach health behaviour people planet data summary rigorous patient consumer safety harnessing online networks improve patient care understanding risks many people share personal information social media commitment continue ensure interests medicines vaccines reach increasing number including experiences using medicines safety patients consumers paramount people low middleincome countries africa valuable data help us improve patient care importance way design undertake supporting efforts strengthen national infrastructures reporting safety information products aim clinical trials product quality assurance building capacity medicine vaccine safety enhancing monitoring reporting adverse events safety assessments establishing global safety support ongoing product usage structure example collaborating government malawi facilitate development pharmacovigilance progressing well reporting system vaccines enhance detection monitoring understanding prevention adverse effects established pharmacovigilance centre excellence us brings together data electronic health databases progress patient reported data social media see case study give us holistic view risks benefits products produced nearly two billion packs medicines million doses vaccines five billion packs consumer keep track risks quality safety standards global healthcare products manufacture medicines risk register ensure patient safety clinical research vaccines according internal quality management system performed audits trials conducted pharmacovigilance centre excellence collects publically available data social media filters unrelated information anything good manufacturing practice regulations behalf third parties see data summary would infringe patient privacy centres analysis helping us regulatory inspections manufacturing sites reducing risks counterfeit products understand benefits products alert us unexpected adverse received observations minor observations increased work border controls improve effects evaluate misuse drugs inspections conducted us food drug anticounterfeiting strategy focusing targeted intelligence twoyear period found approximately million twitter administration fda five resulted form gathering strategic enforcement order prevent counterfeits facebook posts discussing potential adverse events issued sites citing deficiencies current good manufacturing getting onto market reaching consumers medicines well highlighting adverse effects information practices cgmp none observations direct impact given us significant insight inappropriate use drugs important aspect strategy collaboration global product supply sites corrective action plans example discovering patients crushing injecting mitigate observations submitted fda cases customs authorities especially countries counterfeit medicines meant swallowed aware common products known manufactured known major misuse treatments helps us make decisions appropriate july worthing facility uk received warning letter transit hubs counterfeit products recorded trade mark labelling guidance fda arising inspection conducted registrations customs authorities countries analysis evergrowing amount social media data likely months previously responded promptly fda address conducted training sessions customs officials key provide essential insights ways develop better medicines points raised advised programme work ports countries enables authorities identify enhance patient care well advanced seize large shipments counterfeit products destined markets around world performed read online pharmacovigilance audits trials read online time still awaiting reports inspections conducted behalf third parties social media help us hear patients gsk responsible business supplement approach health behaviour people planet data summary minimising animal testing ensuring ethical interactions building trust patient advocacy groups commitment rigorously challenge need commitment demonstrate gsk engage support patient organisations gain insights animal studies work minimise impact interactions patient advocacy groups enable us develop products advocate policies animal welfare investing development political stakeholders conducted appropriately better meet patient needs issued public policy position outlining work patient organisations alternative studies sharing animalbased data ethically transparently high ethical standards apply interactions publish information support provide website track progressing well held patient advocacy leaders summits pals czech republic germany japan portugal pals gather gsk employees patient advocacy leaders together build relationships health policy experts patient advocates progress progress industry supported first asia pacific lung summit animal studies critical part discovery new medicines remained committed transparent ethical interactions connect patient leaders advocate lung health legally required test safety medicines political stakeholders patient advocacy groups communities improve understanding conditions like asthma vaccines remain committed applying rs approach engaging political stakeholders replace reduce refine animal research clear guidelines code conduct ensure response stakeholder feedback disclosing total employee interactions political stakeholders line number animals used research first time values antibribery corruption policy also expect annually used animals thirdparty policy groups engage behalf share rodents number animals used values comprehensive criteria guide selection halved however saw increase following groups integration novartis vaccines business excluding part commitment transparency publish position downward trend continued integrated public policy issues website including intellectual new vaccines sites existing animal programmes property pricing human rights environmental standards developing alternatives animal studies lobbying costs relating gsk activities brussels continue support research new testing systems us registered eu transparency register mimic form function living human tissue organs us federal lobbying register cost representing avoid need animal studies example interests eu institutions range cosponsored challenge set national centre spent lobbying activities replacement refinement reduction animals research us includes operating advocacy offices brussels develop nonanimal model osteoarthritis washington dc cost travel consulting publish also began fiveyear collaboration innovative full list memberships industry trade associations may medicine initiatives vaccine vaccine project aims lobby indirectly behalf online reduce animal testing batch releases vaccines one although gsk make corporate political contributions partner companies provide researchers time us employees financially support individual candidates access research facilities resources amounting political groups political action committee pac million duration project federal election campaign act employees pac read online contributed state federal candidates public policy position political advocacy read online funds contributed state candidates patient group funding use animals rs medicine research federal candidates public policy patient advocacy gsk responsible business supplement approach health behaviour people planet data summary promoting human rights working third parties completed thirdparty risk assessments commitment address un guiding principles commitment seek work third parties includes extensive assessment labour rights fair business business human rights across share commitment high ethical standards practices antibribery corruption environment sustainable operations supplier relationships operate responsible way performance gaps procurement third parties risk assessments underway programme scheduled complete global identified appropriate commit working rollout end date identified activities third party improve performance across thirdparty engagements required improvements address risk management concerns track track ways working also commenced antibribery corruption training initiative third parties seeking ensure third parties work appropriate risk awareness therefore ability manage progress progress conducted thirdparty audits health focus seven areas prioritised based year spend billions pounds tens thousands safety ethics environment labour rights also conducted operations biggest potential affect third parties provision wide range goods services audits focused specifically quality processes human rights access healthcare air quality impact relating increased use preferred suppliers bringing identify areas improvement engage propellants clinical trial standards employment practices patient purchase order spend enables us respective third parties develop improvement plans track safety product counterfeiting use thirdparty suppliers build strong relationships suppliers critical completion overall aim enhancing performance progress area outlined relevant sections business supply chain may also suspend terminate work report third party significant issues identified overseeing third parties managing human rights risks supply chain gsk third parties include suppliers distributors reinforcing requirements labour rights health safety organisations transfer value ensuring communicated consistently continued rollout global thirdparty oversight programme contracts third parties continue monitor existing reached total countries across latin america suppliers screen new suppliers continued rollout south east asia programme aims drive improvements thirdparty oversight programme across latin america supply chain distributor network ensures third parties south east asia see working third parties engage aligned values published statement response uk governments modern slavery act outlines policies processes minimise risk modern slavery within operations supply chain aim ensure compliance policies wider programmes ethical behaviour including speak channels people raise concerns found indications slavery trafficking child labour organisation conducted read online read online human rights statement pharmaceutical supply chain initiative psci modern slavery statement assessments ethical conduct third parties ethical conduct supply chain thirdparty oversight programme working third parties gsk responsible business supplement approach health behaviour people planet data summary people aim create safe inclusive workplace everyone gsk feel able inspired realise potential help us meet global health challenges section developing people inspiring progressing well healthy workplaces promoting inclusion diversity track community volunteering create change completed building future leaders programme provides consistent highquality next generation approach global graduate recruitment leaders new recruits representing nationalities countries gsk responsible business supplement approach health behaviour people planet data summary commitment performance update developing people inspiring healthy workplaces building next generation leaders protecting people future leaders programme delivering commitment continue create working reportable injury illness rate per fresh ideas talent needed continue driving environment inspires people grow hours worked according pharmaceutical safety group success across key markets perform healthy resilient way psg data comparable leading companies sector road safety remains one biggest risks particularly emerging markets majority sales representatives use twowheel progressing well vehicles sadly one sales force died result road traffic incident india try prevent tragedies like reoccurring driver safety programmes india indonesia vietnam people taking part progress health wellbeing attracting retaining talent healthcare company think hard best welcomed graduates postgraduates support health patients consumers future leaders esprit programmes including emerging also employees success global energy markets gsk voted top graduate employer research resilience training programmes innovative ambitious development times top graduate employers partnership prevention programme pp created strong th successive year ranked th overall foundations progress recognised externally programme launched ensure consistent highquality recruited apprentices uk canada ireland named britains healthiest employer vitality healths approach global graduate recruitment development threeyear programme consolidated replaced several existing us expand apprenticeship programmes britains healthiest workplace awards schemes varied approaches provides breadth potential markets gsk ranked th overall rate apprenticeship pp offer almost employees family career pathways rd finance marketing procurement awards uk best apprentice employers option move functions several job rotations members countries unprecedented access preventive trained around people support promotion healthcare services immunisations cancer screening job rotations make programme feedback first second line leader roles continued evolve little extra cost extended services india mentoring coaching constituting formal training global leadership development programmes found russia commonwealth independent states keeping remainder balance enables graduates develop specific managers complete show significant improvement us track achieve goal global coverage skills effective individual role business getting effectiveness based feedback teams broad grasp company learning gsks distinctive global leadership approach coaching colleagues leaders enable others improve reportable injury illness rate programme rated highly participants recent survey alumni performance achieve potential trained per hours worked future leaders programme found respondents felt leaders become coaches strategic use coaching rotations helped develop relevant skills experience recognised worldclass international coach career gsk also indicated felt supported line federations prism award internal analysis shown individuals manager team would recommend programme friends experience either internal job plus coaching external benefits business also clear number geographical executive coaching believe significantly improve ability spread intake means young homegrown diverse demonstrate gsk leadership expectations leaders rooted markets including faster growing emerging responded insights global employee survey countries new recruits representing nationalities employees completed corporate executive team countries eight nations also hosted listening sessions senior leaders conducted follow discussions also introduced pulse surveys better understand employee engagement regular intervals read online read online working gsk future leaders website gsk responsible business supplement approach health behaviour people planet data summary promoting inclusion diversity community volunteering create change percentage women management rose commitment continue promote inclusion women represented corporate executive team commitment extend volunteering opportunities diversity globally gsk cet board compares average bring positive change communities among ftse boards according cranfield board global health providing individual development report also want leaders represent diverse markets track serve recruited people countries completed future leaders graduate programme five different nationalities currently represented cet board progress women management progress female managers began accelerating difference programme supports progression high pulse volunteer partnership programme provides performing female leaders senior roles individual svpvp skillsbased volunteering opportunity eligible employees group coaching sessions male female leaders director matched nonprofit organisation three six months discuss career progression share experiences around fulltime volunteers countries contributed manager participants since promoted million worth skilled services nonprofit partners likely stay gsk colleagues male female total countries worked assignments help meet retention rate last three years global healthcare challenges support un sustainable employees gender development goals particularly health education accelerating difference programme recognised best male female total practice female ftse board report cranfield pulse programme creating positive change total employees university study womens representation boards nonprofit partners agreeing volunteers uks top companies total employees delivered something unique employees could delivered stating impact volunteer felt part efforts promote environment everyone even six months assignment ended employees also feels included established global lesbian gay bisexual benefit pulse volunteers saying transgender lgbt council chaired president something differently gsk return assignment rd endorsed cet council aims engage educate lgbt issues consider gsks potential involvement lgbt issues impact employees patients customers serve achieved score human rights campaign foundations corporate equality index rates workplaces lgbt equality us working global disability council develop online accessibility portal allows employees find information support adjustments working environments worth skilled services nonprofit partners expanded internship programme young people pulse partnership programme learning difficulties stevenage bioscience hub uk read online employee volunteering read online women pulse volunteers inclusion diversity management pulse impact report gsk responsible business supplement approach health behaviour people planet data summary planet aim reduce environmental impacts across value chain extending access products people need minimising carbon footprint reducing local water impacts cutting operational waste section aiming carbon neutral work needed reducing water impact progressing well reducing waste track reducing emissions investing renewable energy infrastructure converting lowemission fuels improving energy efficiency cut operations emissions operations reduced operational emissions scope since baseline gsk responsible business supplement approach health behaviour people planet data summary ccoommmmiittmmeenntt ppeerrffoorrmmaannccee uuppddaattee aiming carbon neutral supply chain represents largest part value chain footprint supplier environmental sustainability awards went commitment reduce overall carbon footprint followed use products operations aitken spence printing packaging company sri lanka vs carbon logistics end life disposal make remaining dow chemical company neutral value chain largest value chain impact focus helping suppliers certain products disproportionate effect value chain make environmental improvements example suppliers emissions particularly ventolin propellantbased inhalers work needed covering billion spend direct raw materials disclose emit greenhouse gases use continue research solutions information ecodesk online platform monitor issue including changing way manufacture reduce promote environmental improvements supply chain addition amount propellant used maintaining efficacy patients suppliers use online sustainability collaboration progress platform gsk supplier exchange share best practice operational emissions scope totalled million tonnes co e broadly previous scope ghg emission scope ghg emission year represents decrease baseline thousand tonnes co e thousand tonnes co e reduce emissions continued focus energy efficiency renewable energy investment sustainable buildings see case study revised calculation method scope emissions current ghg protocol methodology includes impact purchased services capital investments fuel energy related activities logistics upstream supply chain business travel commuting based latest methodology increased baseline figure million tonnes co e million tonnes co e overall carbon footprint scope increased million tonnes co e million tonnes co e due novartis integration represents increase overall footprint versus baseline excluding novartis footprint remained flat despite volume medicines vaccines consumer healthcare products shipped factories increased approximately target target period onsite fuel use scope emissions purchased goods services energy related sales force vehicles electricity steam business travel commuting product use inhaler propellant losses ownstrean logistics end life emissions investments read online ur recently available scope data publish data online late aiming carbon neutral gsk responsible business supplement approach health behaviour people planet data summary reducing water impact investing sustainable buildings sawaipura nearly water around quarter designing sustainable buildings across global commitment reduce water impact across amount water three horlicks factories across india use operations minimise environmental impact value chain vs operations punjab region india partner others improve local progressing well farmers water management conservation practices fixing leaks harvesting rainwater managing timing crop sowing coincide rainfall raising awareness education programmes villages across region water progress also needed produce food crops used fodder cows training farmers make use surplus grass used used million water across operations cow feed droughts means buy fodder less representing reduction compared able sustain milk yields yearround baseline continue look ways use water efficiently reduce total water consumption across operations operational water use last five years refined approach assessing million water impact value chain taking consideration four new building ware uk needs carefully controlled ambient areas water scarcity local water quality health social risks temperature humidity store pharmaceutical samples building design makes resilient outdoor temperature changes regulatory reputational risks value chain able minimising environmental impacts use identify across value chain focus interventions solar panels roof generate twice much energy building needs feeding rest back grid inside whilst remains difficult report specific reductions water impact rooms plenty natural light ventilation heated sun across value chain able identify regions clever building design hot water comes onsite water use highest impact continue focus reducing combined heat power plant innovative building water use operations supply chain design date continues transformation sites across particular focus gsks sites waterscarce regions global network agricultural supply chain horlicks india addition new one us regional operations hubs philadelphia awarded water stewardship policy reinforces commitment reduce leed platinum highest rating international green water impact across value chain engagement buildings certification uses energy traditional collaboration key stakeholders building state art factory bangalore india solar panels target generate kw power discharge liquids together alternative development initiatives indian learn sustainable building techniques sustainable development ngo also supporting communities used industrial purposes putting knowledge practice horlicks supply chain improve water management similar projects uk gsk funding led construction agricultural yields innovative project rajasthan arid region countrys first ever carbon neutral laboratory nottingham india replenishing local water source village reduced water use across operations read online energy traditional water stewardship policy building operations reducing water impact compared hub philadelphia gsk responsible business supplement approach health behaviour people planet data summary reducing waste emerging environmental issues external recognition climate change water efforts microbeads microplastics gsk committed managing reducing environmental commitment reduce operational gsk included prestigious cdp lists climate impacts products waste vs water microbeads defined solid plastic particles less mm size used rinse cosmetic personal care track products cleanse exfoliate gsk use microbeads products plans future progress additional step evaluating portfolio determine reformulation opportunities products use inactive operations produced tonnes waste plastic ingredients date identified small number less previous year baseline products plan reformulate initiatives take majority recycled incinerated recover approximately three years complete phase market energy sent landfill around sites achieved zero waste landfill repurposing materials continue work closely industry associations ensure would otherwise go waste using wastetoenergy services appropriate definitions consistently applied industry enough time reformulate transition new working company shop organisation redistributes products marketplace surplus food products uk diverted tonnes consumer products going waste waste water pollution supply chain close expiry date conventional retailers sell also increasing pressure pharmaceutical industry efforts reduce carbon emissions acknowledged distributed stores including targeting people broad group stakeholders tackle waste water pollution inclusion climate list cdp assessed companies globally poverty exploring ways expand pilot supply chain particular links antimicrobial across industry sectors one companies locations products resistance amr applicants seven healthcare companies alisted stringent policies place manage environmental high rating reflects significant steps taken help meet operational waste impact pharmaceutical manufacturing including goal becoming carbon neutral continuing grow thousand tonnes antibiotics committed carrying due diligence business meet healthcare needs people example close monitoring auditing thirdparty suppliers moved towards environmentally sustainable approach environmental practices treating respiratory disease included reducing emissions manufacture inhalers launching complete cycle amr complex problem driven number diverse factors scheme first kind work pharmacists patients essential united global efforts maintained recover recycle inhalers steps helped us reduce address practices driving resistance encourage operational emissions since investment create future pipeline new treatments read also one applicants companies amr efforts healthcare company included water list success reflects achievements reducing water usage since commitment water stewardship commitment read online read online reducing waste pharmaceuticals environment external recognition gsk responsible business supplement approach health behaviour people planet data summary data summary notes health better access number doses synflorix supplied gavi million medicines vaccines number doses rotarix vaccine supplied gavi million value gsk medicine vaccines prescribed us patient assistance programme cost goods sold million usd number patients reached us patient assistance programme community investment cash million product inkind million time million management costs million strengthening healthcare health worker training programmes million infrastructure healthcare workers partners trained cumulative number people reached reinvestment programme million cumulative neglected tropical diseases albendazole tablets help lf elimination million albendazole tablets help treat intestinal worms million eradicating polio number doses oral polio vaccine delivered global polio eradication initiative million behaviour compliance employees disciplined policy violations employees dismissed agreed leave company voluntarily documented warnings total number marketing promotional activity violations number contacts made speak channels clinical trial data publicly available trial result summaries cumulative number studies clinical study reports posted register number trials listed patient level data available request number research teams granted access gsk trial data figures include healthworker programmes beyond least developed country ldc programmes figure includes projects related novartis assets projects fully transitioned novartis report therefore incorporate removal projects total gsk responsible business supplement approach health behaviour people planet data summary notes behaviour clinical research audits investigator sites audits gsk processes audits gsk local operating companies investigations suspected irregularities audits contract research organisations total audits undertaken anticounterfeiting number trainings customs officials ensuring quality manufacturing number regulatory inspections pharmaceutical business supply number regulatory inspections vaccines business number regulatory inspections consumer healthcare business people health safety number fatalities reportable incidents lost time lost time reportable injury illness rate reportable incidents without lost time reportable injury illness rate talent leadership development total number coaching assignments number graduates recruited future leaders programme number postgraduates recruited esprit programme number apprentices recruited inclusion diversity percentage women management total percentage employees emerging markets asiapacific japan volunteering number employees completing pulse health safety data restated include former novartis sites acquired gsk responsible business supplement approach health behaviour people planet data summary notes planet carbon scope ghg emissions tonnes co e gas fuel electricity steam propellant emissions manufacture inhalers sales force travel emissions total scope ghg emissions tonnes coe purchased goods services product logistics business travel air commuting propellant emissions use inhalers use products disposal products emissions total water water use operations million cubic metres waste total waste generated thousand tonnes waste landfill thousand tonnes compliance internal audits number environmental fines environmental remediation spend million propellant emissions data collected internal systems accurate picture scope ghg emissions later year detailed breakdown environmental fines available responsible business supplement fines mostly due discovery waste tank upper merrion site comply local regulations plus fine paid hamilton site failure submit risk management plan storage use chloroform take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies used gsk responsible business supplement approach health behaviour people planet data summary summary assurance statement bureau veritas summary independent assurance statement statement independence impartiality competence reporting bureau veritas uk ltd engaged glaxosmithkline gsk bureau veritas independent professional services company report performance annually report plc provide independent assurance environment health specialises quality environment health safety social safety ehs performance data objective bureau accountability years history assurance team part commitment open transparent veritas work express opinion accuracy reliability extensive experience environmental social ethical health business activities responsible business also ehs data provide summary findings safety information systems processes bureau veritas code covered annual report ethics ensures staff members avoid conflict interest full assurance statement found includes details maintain high ethical standards business activities data coverage scope work methodology findings recommendations data report relates gsks global operations improvement gsks response assurance calendar year except otherwise stated pleased bureau veritas findings gsks established summary scope methodology data environment health safety sections processes managing ehs data thank ssessment performance data contained within ehs independently verified bureau veritas brand names recommendations committed continuously improving data table associated data management processes appearing italics throughout report trade marks either data collection reporting processes order provide involved detailed review integrity selected datasets owned andor licensed gsk associated companies accurate ehs data public responsible business aggregation checking processes corporate level supplement website reporting standards well sampling data back source five gsk sites sites index global reporting initiative guidelines shows chosen represent significant impact gsk operations elements covered report signatory geographical spread un global compact publish annual communication nterviews senior ehs staff understand gsks objectives progress demonstrate uphold ten principles approach data collation management available gskcom opinion recommendations policies codes standards based assurance work carried evidence number policies codes standards accessible presented per scope work nothing came website covering range different areas public attention suggest health business integrity environment found downloaded reported data provide fair representation gsks ehsrelated activities performance defined feedback counts period welcome feedback responsible business performance reporting also request receive significant omissions material misstatements regular updates progress could affect stakeholders ability make informed judgements gsks ehs performance please contact us csrcontactgskcom since implementation ehs central comprehensive effective improving submissions data refinement ehs reporting unifying hours worked calculation methodology across business groups ensuring emission factors used date particularly ones used thirdparty data providers eg business travel london february